Oral physiological magnesium supplementation for 6 weeks with 1 g/d magnesium oxide does not affect increased Lp(a) levels in hypercholesterolaemic subjects

Magnes Res. 1996 Jun;9(2):129-32.

Abstract

Twenty hyperlipidaemic patients on a cholesterol-poor diet were selected on the basis of a raised lipoprotein (a) (Lp(a); apo (a) > 300 U/litre) and treated with 1000 mg MgO per day during 6 weeks. Serum magnesium slightly increased compared to pretreatment levels (P < 0.001). Serum apo(a) concentrations (mean +/- S.D.) were not affected: pretreatment level 963 +/- 552 U/litre; during treatment 999 +/- 536 U/litre; and after washout 995 +/- 524 U/litre. Serum cholesterol increased slightly during MgO treatment because of an increase in LDL-cholesterol (10 per cent) and returned to pretreatment levels after a washout period.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Administration, Oral
  • Apolipoproteins A / drug effects
  • Apolipoproteins A / metabolism*
  • Cholesterol / blood
  • Female
  • Humans
  • Hypercholesterolemia / drug therapy*
  • Hypercholesterolemia / metabolism*
  • Lipoproteins, HDL / blood
  • Lipoproteins, HDL / drug effects
  • Lipoproteins, LDL / blood
  • Lipoproteins, LDL / drug effects
  • Magnesium / blood
  • Magnesium Oxide / administration & dosage
  • Magnesium Oxide / pharmacology*
  • Magnesium Oxide / therapeutic use
  • Male
  • Prospective Studies
  • Triglycerides / metabolism

Substances

  • Apolipoproteins A
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Triglycerides
  • Magnesium Oxide
  • Cholesterol
  • Magnesium